Clinical Trials Browser

Developmental Disabilities, Communication Disorders, Deglutition Disorders, Head and Neck Neoplasms, Language Development Disorders, Language Disorders, Speech, Stuttering, Hearing Loss

NCT01451853 2017-09-25

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Phase 2 Unknown

80 enrolled

Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

Clinical Trials

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)

Head and Neck Cancer Survivorship Ototoxicity Screening (SOS)

MRI-based Synthetic CT Images of the Head and Neck

Providing Speech Therapy Awareness in Private Schools

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss